分组1 - Biogen Inc. reported quarterly earnings of $1.99 per share, exceeding the Zacks Consensus Estimate of $1.61 per share, but down from $3.44 per share a year ago, representing an earnings surprise of +23.40% [1] - The company posted revenues of $2.28 billion for the quarter ended December 2025, surpassing the Zacks Consensus Estimate by 3.06%, compared to $2.45 billion in revenues a year ago [2] - Biogen has surpassed consensus EPS estimates three times over the last four quarters and topped consensus revenue estimates four times during the same period [2] 分组2 - The stock's immediate price movement will depend on management's commentary during the earnings call, with Biogen shares up about 5.3% since the beginning of the year, while the S&P 500 has declined by 0.7% [3] - The current consensus EPS estimate for the coming quarter is $3.48 on revenues of $2.28 billion, and for the current fiscal year, it is $14.84 on revenues of $9.32 billion [7] - The Medical - Biomedical and Genetics industry, to which Biogen belongs, is currently in the top 37% of Zacks industries, indicating a favorable outlook compared to the bottom 50% [8]

Group 1 - Curreen Capital reported a return of 10.5% in Q4 2025 and 30.97% for the full year, focusing on "ugly ducklings" that are well-managed and attractively priced [1] - The firm's top five holdings contributed significantly to its performance, with Fortrea Holdings Inc. being a key position [1] - Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization with a market capitalization of $1.553 billion, closing at $16.81 per share on January 30, 2026 [2] Group 2 - Fortrea Holdings Inc. had a one-month return of 1.14% and a 52-week gain of 7.28% [2] - Curreen Capital's investment strategy includes identifying "Crazy Cheap" stocks, where Fortrea is classified due to its significant price drop relative to its downside valuation [3] - Fortrea Holdings Inc. was held by 37 hedge fund portfolios at the end of Q3, a slight decrease from 38 in the previous quarter [4]

Group 1 - Fortrea Holdings Inc. (NASDAQ:FTRE) is considered one of the best young stocks to buy and hold for three years, with recent price target adjustments from Mizuho and Truist indicating positive market sentiment [1][2][3] - Mizuho raised its price target on Fortrea to $15 from $13 while maintaining a Neutral rating, citing a sequential slowdown in healthcare utilization despite easier comparisons from the previous year [1] - Truist upgraded Fortrea from Hold to Buy, setting a new price target of $22, based on enhanced operational performance, emerging commercial strength, and improved profit margins under new leadership [2] - Evercore ISI upgraded Fortrea from In Line to Outperform, significantly raising its price target to $25 from $14, highlighting an accelerating biopharma cycle and improved execution as key drivers [3] Group 2 - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotech, and medical device customers globally [4]

Financial Performance - The company's total adjusted EBITDA for 3Q25 was $610.3 million[6], compared to $538.9 million in 3Q24[6] - For the nine months ended September 30, 2025, the adjusted net income attributable to Labcorp Holdings Inc was $1038.3 million, compared to $939.9 million for the same period in 2024[22] - The adjusted earnings per share for the three months ended September 30, 2025, was $4.18, compared to $3.50 for the same period in 2024[23] Revenue Analysis - Enterprise revenues, as reported, for 3Q25 were $3,564 million, an increase of 8.6% year-over-year[8] - Diagnostics Laboratories revenues, as reported, for 3Q25 were $2,770 million, an increase of 8.5% year-over-year[8] - Biopharma Laboratory Services revenues, as reported, for 3Q25 were $799 million, an increase of 8.3% year-over-year[8] - The company's revenue growth in Diagnostics Laboratories for 3Q25 was primarily driven by volume (4.7%) and price/mix (3.7%)[15] Outlook for 2025 - The company updated its 2025 revenue guidance for Labcorp Enterprise to a range of $13.97 billion to $14.05 billion, representing a growth of 7.4% to 8.0% versus 2024 results[18] - The company updated its 2025 adjusted EPS guidance to a range of $16.15 to $16.50, representing a growth of 10.8% to 13.2% versus 2024 results[18] Biopharma Laboratory Services - The trailing twelve-month net orders for Biopharma Laboratory Services ending September 30, 2025, were $3.34 billion, with a net book-to-bill ratio of 1.09x[17]

Core Insights - The U.S. market is experiencing significant turbulence due to renewed U.S.-China trade tensions, an ongoing government shutdown, and the start of the third-quarter earnings season [1][11] - Investors are closely monitoring key reports on inflation and jobs, as well as remarks from Fed Chair Powell that may influence rate expectations [2] - Amidst these uncertainties, value investing is gaining traction, focusing on fundamentally strong companies that are undervalued [2][11] Value Investing and Earnings Yield - Earnings yield is a crucial metric for identifying attractive value opportunities, calculated as annual earnings per share (EPS) divided by the market price [4] - Stocks with higher earnings yield are considered undervalued compared to those with lower earnings yield, which are seen as overpriced [5] - A stock's yield should be compared to the 10-year Treasury yield to assess its relative value; a higher yield indicates a potentially better investment for value investors [6] Screening Criteria for Stock Selection - The primary screening criterion is an earnings yield greater than 10%, supplemented by additional parameters such as estimated EPS growth and average daily trading volume [7][8] - Stocks with a Zacks Rank of 1 (Strong Buy) or 2 (Buy) are expected to outperform peers in various market conditions [9] Top Stock Picks - **Allied Gold Corporation (AAUC)**: Expected EPS growth of 907% and 193% for 2025 and 2026, respectively, with a Zacks Rank 1 [12] - **Micron Technology Inc. (MU)**: Anticipated EPS growth of 100% and 12% for fiscal 2026 and 2027, respectively, also holding a Zacks Rank 1 [13] - **Fortrea Holdings Inc. (FTRE)**: Projected EPS growth of 63.6% and 64.5% for 2025 and 2026, with a Zacks Rank 1 [14] - **StoneCo Ltd. (STNE)**: Expected EPS growth of 20% and 17% for 2025 and 2026, respectively, and a Zacks Rank 1 [15] - **HF Sinclair Corporation (DINO)**: Forecasted EPS growth of 257.4% and 26.4% for 2025 and 2026, with a Zacks Rank 1 [16]

Core Insights - Fortrea Holdings Inc. is identified as a cheap stock with potential for growth over the next five years, with Barclays raising its price target to $8 from $6 while maintaining an Underweight rating [1][3] Financial Performance - In Q2, Fortrea reported quarterly revenue of $710.3 million, reflecting a year-over-year increase of 7.23% [1][2] - The company achieved an Adjusted EBITDA of $54.9 million and an adjusted net income per diluted share of $0.19, prompting management to raise its full-year 2025 revenue guidance to a range of $2.6 to $2.7 billion [2] - Despite revenue growth, Fortrea recorded a GAAP net loss of $374.9 million, or $4.14 per diluted share, primarily due to a non-cash goodwill impairment charge of $309.1 million [3] Business Overview - Fortrea Holdings Inc. operates as a contract research organization, providing biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers [4] - The company's backlog stood at $7.547 billion, indicating a strong pipeline of future business [3] - Fortrea affirmed that its cost-saving initiatives are on track, which may enhance future profitability [3]

Company Overview - Amarin (AMRN) shares increased by 12.5% to close at $18.84, supported by high trading volume, compared to an 11.4% gain over the past four weeks [1] - The price surge is linked to rising investor confidence in Vascepa, Amarin's sole marketed drug, which treats severe hypertriglyceridemia [1] Earnings Expectations - Amarin is projected to report quarterly earnings of $0.31 per share, reflecting a year-over-year increase of 131% [2] - Expected revenues are $42.36 million, showing a slight increase of 0.2% from the same quarter last year [2] Stock Performance Insights - The consensus EPS estimate for Amarin has remained stable over the last 30 days, indicating that stock price movements may not sustain without earnings estimate revisions [3] - The stock currently holds a Zacks Rank of 2 (Buy), suggesting positive market sentiment [4] Industry Comparison - Amarin operates within the Zacks Medical - Biomedical and Genetics industry, where Fortrea Holdings Inc. (FTRE) has seen a decline of 1.6% to $9.45, with a monthly return of -8.7% [4] - Fortrea's consensus EPS estimate has decreased by 13.3% over the past month to $0.15, representing a 34.8% decline from the previous year [5]

Core Viewpoint - A lawsuit is pending against Semtech Corporation (NASDAQ: SMTC) for alleged violations of securities laws, primarily related to the company's CopperEdge products not meeting customer needs, which could impact sales forecasts for fiscal 2026 [2][3]. Group 1: Lawsuit Details - The lawsuit was initiated by an investor on February 20, 2025, claiming that Semtech Corporation failed to disclose critical information regarding its CopperEdge products [2]. - Allegations include that the CopperEdge products required specific rack architecture changes and would not achieve expected sales growth during fiscal 2026, leading to misleading positive statements from the company [2]. - A consolidated complaint was filed on July 14, 2025, and the defendants submitted a motion to dismiss the case on August 11, 2025 [3]. Group 2: Investor Information - Investors who purchased shares of Semtech Corporation prior to August 2024 and continue to hold them are encouraged to contact the Shareholders Foundation for options regarding the lawsuit [1][3].

Company Overview - Fortrea Holdings Inc. (NASDAQ:FTRE) is a contract research organization that provides biopharmaceutical product and medical device development solutions to pharmaceutical, biotechnology, and medical device customers worldwide [4] Financial Performance - For Q2 2025, Fortrea reported revenue of $710.3 million, an increase from $662.4 million in Q2 2024 [2] - The company experienced a GAAP net loss of $374.9 million, which included a non-cash goodwill impairment charge of $309.1 million, resulting in a GAAP loss of $4.14 per diluted share [2] - Despite the loss, Fortrea achieved a positive adjusted net income of $17.6 million, or $0.19 per diluted share, a turnaround from an adjusted net loss of $2.3 million in Q2 2024 [3] - Fortrea is increasing its 2025 revenue guidance to a range of $2,600 to $2,700 million and affirming its adjusted EBITDA guidance for the full year in the range of $170 million to $200 million [3] Market Sentiment - Jefferies raised the price target on Fortrea to $9.50 from $7 while maintaining a Hold rating, driven by stronger biotech funding in the last three months and improved bookings across the contract research organization industry [1][3]

Company Performance - AC Immune reported a quarterly loss of $0.25 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.20, marking an earnings surprise of -25.00% [1] - The company posted revenues of $1.58 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 57.3%, compared to revenues of $0.76 million a year ago [2] - Over the last four quarters, AC Immune has surpassed consensus EPS estimates three times but has topped consensus revenue estimates only once [2] Stock Outlook - AC Immune shares have declined approximately 18.7% since the beginning of the year, contrasting with the S&P 500's gain of 7.6% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is -$0.24 on revenues of $1.14 million, and for the current fiscal year, it is -$0.93 on revenues of $6.04 million [7] Industry Context - The Medical - Biomedical and Genetics industry, to which AC Immune belongs, is currently ranked in the bottom 43% of over 250 Zacks industries, indicating a challenging environment [8] - Empirical research suggests a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact AC Immune's stock performance [5][6]